Ascendis Pharma A/SASND
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $867.51M, growing 135.3% year-over-year. TTM net income stood at $506.60M (248.3% growth). Quarterly EBITDA was $29.51M and operating income was $25.22M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze ASND growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters